ACC 2020 Wrap Up: An Analysis of the Late-breaking Trials

Dr Nicolas M Van Mieghem obtained his medical degree and cardiology degree at the Catholic University of Leuven, Belgium. After subsequent fellowships in interventional cardiology in Ziekenhuis Oost-Limburg Genk, Belgium, Lenox Hill Hospital, New York, US and Erasmus Medical Center, Rotterdam, the Netherlands, he joined the department of interventional cardiology at the Thoraxcenter, Erasmus Medical Center, as a senior staff member in February 2010. 

He is involved in the percutaneous coronary interventions and structural heart program. He obtained the degree of PhD based upon his research in transcatheter valve therapies. So far he has published and co-authored approximately 130 scientific papers in peer-reviewed journals. 

Dr Van Mieghem is principle investigator and steering committee member in multiple ongoing international trials evaluating various coronary and transcatheter valve technologies. He is a Fellow of the European Society of Cardiology and is currently Medical Director of the department of Interventional cardiology at the Thoraxcenter.

Dr Joost Daemen, MD, PhD obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam. 

Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of 4 trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.